AVIPIRAVIR 200 MG 40 TABLETS
Not only does favipiravir inhibit replication of influenza A and B, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
ACTIVE INGREDIENT OF AVIPIRAVIR
favipiravir
MECHANISM OF ACTION
Favipiravir (T-705) is a synthetic prodrug, first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyoma chemicals. A lead compound, A/PR/8/34, later designated as T-1105, and its derivatives have antiviral activities. Chemical modification of the Pyrazine moiety of T-1105 derives Favipiravir.
THERAPEUTIC USES AND INDICATIONS
Not only does favipiravir inhibit replication of influenza A and B, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir treats life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
Clinical trials in COVID-19
Favipiravir is useful in a small case series consisting of 11 serious patients with COVID-19 in Japan. The median age, time from symptom onset to admission in the ICU, and PaO2/FiO2 ratio on admission were 68 years (IQR 60–69), 8 days (IQR 7–11), and 131 (IQR 114–198) respectively. All patients needed oxygen therapy, eight patients (73%) needed invasive mechanical ventilation, and 3 patients (27%) needed extracorporeal membrane oxygenation (ECMO).
Of the 11 patients, 7 didn’t need mechanical ventilation. Nine and 7 patients were discharged from the ICU and the hospital, respectively.
READ MORE
karim (verified owner) –
I used it under the supervision of a doctor when I was infected with Corona